ArticleOPEN ACCESS

Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

Nature Medicine
DOI: 10.1038/s41591-022-01827-x
3Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In the version of this article initially published, the name of the Edward P. Evans Foundation was shown incorrectly in the first sentence of the Acknowledgements. The name has been corrected in the HTML and PDF versions of the paper.

Cite

CITATION STYLE

APA

Ganan-Gomez, I., Yang, H., Ma, F., Montalban-Bravo, G., Thongon, N., Marchica, V., … Colla, S. (2022, May 1). Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4). Nature Medicine. Nature Research. https://doi.org/10.1038/s41591-022-01827-x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free